Recombinant human growth hormone treatment, using two dose regimens in children with chronic renal failure -: A report on linear growth and adverse effects

The aim of this study was to study the efficiency and the adverse effects of 2 or 4 IU/m(2)/day of growth hormone (GH) in the first year and 4 IU/m(2)/day in the second. Of 29 growth-retarded children with chronic renal failure (CRF) (aged 3.4-15.1 years), 23 completed the first year of therapy, and 16 completed the second year. Height velocity SDS (HVSDS) increased in the first year in the low-dose group with 3.0, and 3.8 in the high-dose group. In the second year, HVSDS increased by 1.3 in the low-dose group and by 2.1 in high-dose group (p<0.05). The IGF-I/IGFBP-3 ratio rose identically during the first year (p<0.01). The retarded bone age did not advance inappropriately. The integrated insulin levels (AUC) increased significantly after 1 year of therapy in both groups. HbA(1c) levels did not change. The number of adverse events was highest in the low-dose group, in which one patient developed overt insulin dependent diabetes mellitus. In conclusion, glucose metabolism should be monitored in children with CRF during rhGH-treatment. GH therapy in our patients resulted in a significant increase in height velocity with no inappropriate bone age progression and few serious adverse effects, all without relation to the dose of rhGH. The low start dose (2 IU/m(2)/day) was of no advantage compared to the high dose.